##fileformat=VCFv4.2
##fileDate=20220831
##reference=ftp://ftp.ncbi.nih.gov/genbank/genomes/Eukaryotes/vertebrates_mammals/Homo_sapiens/GRCh37/special_requests/GRCh37-lite.fa.gz
##source=CIViCpy_v2.0.0-alpha
##aboutURL=https://civicdb.org/help/evidence/overview
##INFO=<ID=GN,Number=1,Type=String,Description="HGNC Gene Symbol">
##INFO=<ID=VT,Number=1,Type=String,Description="CIViC Variant Name">
##INFO=<ID=CSQ,Number=.,Type=String,Description="Consequence annotations from CIViC. Format: Allele|Consequence|SYMBOL|Entrez Gene ID|Feature_type|Feature|HGVSc|HGVSp|CIViC Variant Name|CIViC Variant ID|CIViC Variant Aliases|CIViC HGVS|Allele Registry ID|ClinVar IDs|CIViC Variant Evidence Score|CIViC Entity Type|CIViC Entity ID|CIViC Entity URL|CIViC Entity Source|CIViC Entity Variant Origin|CIViC Entity Status|CIViC Entity Clinical Significance|CIViC Entity Direction|CIViC Entity Disease|CIViC Entity Drugs|CIViC Entity Drug Interaction Type|CIViC Evidence Phenotypes|CIViC Evidence Level|CIViC Evidence Rating|CIViC Assertion ACMG Codes|CIViC Assertion AMP Category|CIViC Assertion NCCN Guideline|CIVIC Assertion Regulatory Approval|CIVIC Assertion FDA Companion Test ">
#CHROM	POS	ID	REF	ALT	QUAL	FILTER	INFO
1	8073509	691	C	A	.	.	GN=ERRFI1;VT=E384*;CSQ=A|Stop_Gained&Loss_Of_Function_Variant|ERRFI1|54206|transcript|ENST00000377482.5|||E384*|691|E384X&GLU384TER|NC\x5F000001\x2E10\x3Ag\x2E8073509C\x3EA|CA338219584|NONE_FOUND|5.0|evidence|1724|https://civicdb.org/links/evidence/1724|24550739_(PUBMED)|SOMATIC|accepted|SENSITIVITYRESPONSE|SUPPORTS|Cholangiocarcinoma_(DOID_4947)|Erlotinib_(NCIt_ID_C65530)|||C|2|||||
1	11177096	609	C	A	.	.	GN=MTOR;VT=M2327I;CSQ=A|Missense_Variant|MTOR|2475|transcript|ENST00000361445.4|ENST00000361445.4:c.6981G>T||M2327I|609|MET2327ILE|NC\x5F000001\x2E10\x3Ag\x2E11177096C\x3EA&ENST00000361445\x2E4\x3Ac\x2E6981G\x3ET|CA338383476|NONE_FOUND|7.0|evidence|1544|https://civicdb.org/links/evidence/1544|27279227_(PUBMED)|SOMATIC|accepted|RESISTANCE|SUPPORTS|Breast_Cancer_(DOID_1612)|MTOR_Kinase_Inhibitor_AZD8055_(NCIt_ID_C78856)|||D|4|||||,A|Missense_Variant|MTOR|2475|transcript|ENST00000361445.4|ENST00000361445.4:c.6981G>T||M2327I|609|MET2327ILE|NC\x5F000001\x2E10\x3Ag\x2E11177096C\x3EA&ENST00000361445\x2E4\x3Ac\x2E6981G\x3ET|CA338383476|NONE_FOUND|7.0|evidence|10082|https://civicdb.org/links/evidence/10082|27279227_(PUBMED)|SOMATIC|submitted|SENSITIVITYRESPONSE|SUPPORTS|Breast_Cancer_(DOID_1612)|Sirolimus_(NCIt_ID_C1212)&RapaLink-1|SUBSTITUTES||D|4|||||,A|Missense_Variant|MTOR|2475|transcript|ENST00000361445.4|ENST00000361445.4:c.6981G>T||M2327I|609|MET2327ILE|NC\x5F000001\x2E10\x3Ag\x2E11177096C\x3EA&ENST00000361445\x2E4\x3Ac\x2E6981G\x3ET|CA338383476|NONE_FOUND|7.0|evidence|1545|https://civicdb.org/links/evidence/1545|27279227_(PUBMED)|SOMATIC|accepted|RESISTANCE|DOES_NOT_SUPPORT|Breast_Cancer_(DOID_1612)|RapaLink-1&Sirolimus_(NCIt_ID_C1212)|SUBSTITUTES||D|3|||||
1	11184573	542	G	T	.	.	GN=MTOR;VT=S2215Y;CSQ=T|Missense_Variant|MTOR|2475|transcript|ENST00000361445.4|ENST00000361445.4:c.6644C>A||S2215Y|542|SER2215TYR|NC\x5F000001\x2E10\x3Ag\x2E11184573G\x3ET&ENST00000361445\x2E4\x3Ac\x2E6644C\x3EA&NM\x5F004958\x2E3\x3Ac\x2E6644C\x3EA&NP\x5F004949\x2E1\x3Ap\x2ESer2215Tyr|CA16602587|376129|2.0|evidence|1319|https://civicdb.org/links/evidence/1319|24631838_(PUBMED)|SOMATIC|accepted|SENSITIVITYRESPONSE|SUPPORTS|Endometrial_Adenocarcinoma_(DOID_2870)|Sirolimus_(NCIt_ID_C1212)|||D|2|||||
